Nateglinide
Nateglinide, which is a derivative of D-phenylalanine, is a non-sulfonylurea insulin secretagogue. It belongs to the meglitinide class of oral hypoglycemic agents. It causes insulin secretion via inhibition of the ATP-sensitive potassium channels in the pancreatic beta cells.Management of Type-2 (non-insulin dependent) diabetes that cannot be controlled with diet and exercise, as a single agent or in combination for hypoglycemia not completely controlled with metformin.
Nateglinide should be taken one hr to 30 minutes prior to meal. The recommended starting and maintenance dose is 120mg, three times a day before meals.
Hypersensitivity, Diabetic ketoacidosis with Type 1 diabetes.
Hypoglycemia : Geratric patients, malnourished patients, and those with adrenal or pituitary insufficiency are more susceptible to the glucose lowering effect of these treatments. The risk of hypoglycemia may be incerased by strenuous physical exercise, ingestion of alcohol, insufficient caloric intake on an acute ro chronic basis, or combinations with other oral antidiabetic agents. Hepatic impairment, loss of glyceamic control, Pregnancy and lactation.
Dizziness, diarrhea, nausea, hypoglycemia, back pain, arthropathy, upper respiratory tract infection, bronchitis, coughing, flu like symptoms, accidental injuries.
Nateglinide may interact with certain medications, including beta-blockers, gemfibrozil, and rifampicin, potentially altering their effectiveness or increasing the risk of side effects.
